50 employees
AlloCure is focused on developing cell therapies for the treatment of various kidney diseases, organ transplants, and multi-organ injuries.
2008
$25M
from 3 investors over 3 rounds
AlloCure raised $25M on April 2, 2012
Investors: Lundbeckfonden / Lundbeck Foundation and Novo Holdings
AlloCure raised $15M on July 2, 2008
Investors: Novo Holdings